New drug cocktail trial targets rare blood cancer
NCT ID NCT04624906
Summary
This study is testing a combination of three drugs for people newly diagnosed with Waldenstrom's macroglobulinemia, a rare type of blood cancer. Participants receive standard chemotherapy (bendamustine and rituximab) for six months, plus a newer pill called acalabrutinib for one year. The main goal is to see how well this combination controls the cancer and leads to deep responses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Quebec - University Laval
Laval, Quebec, Canada
-
Cross Cancer Institute
Edmonton, Alberta, Canada
-
Hamilton Health Sciences Centre - Juravinksi
Hamilton, Ontario, Canada
-
McGill University Health Centre
Montreal, Quebec, Canada
-
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
The Ottawa Hospital
Ottawa, Ontario, Canada
-
Tom Baker Cancer Centre
Calgary, Alberta, Canada
-
Vancouver General Hospital
Vancouver, British Columbia, Canada
Conditions
Explore the condition pages connected to this study.